US Employers Reassess GLP-1 Obesity Drug Coverage Amid Rising Demand

A number of U.S. employers plan to eliminate coverage for GLP-1 obesity drugs, like Novo Nordisk's Wegovy, in 2027. This decision counters savings from lower drug prices amid increasing usage of these medications. The move could affect access to these drugs for weight loss through employer-sponsored health plans.

In a significant policy shift, some U.S. employers are set to stop covering GLP-1 obesity drugs in 2027, including popular medications like Wegovy and Zepbound. This comes as the utilization of these drugs rises, despite reduced prices.

The Business Group on Health reported that approximately 10% of current employer sponsors of GLP-1 drug coverage for weight loss are considering dropping these benefits. The decision emerges amid a backdrop of improved pricing for the drugs, which will likely see a surge in demand as their popularity continues to grow.

This trend suggests a potential impact on employee health benefits nationwide, as more individuals seek these medications as part of their weight management strategies.